Cargando…

An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer

Small cell lung cancer (SCLC) is a highly proliferative, aggressive form of lung cancer that carries a poor prognosis. Recent approvals with new therapeutic options represent the first in more than a decade for SCLC. Lurbinectedin, a newly approved second-line option, is a synthetic alkaloid that co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Shetal, Petty, William Jeffrey, Sands, Jacob M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/ https://www.ncbi.nlm.nih.gov/pubmed/34104228 http://dx.doi.org/10.1177/17588359211020529

Ejemplares similares

Second‐line lurbinectedin as a new treatment option for small‐cell lung cancer: Preliminary results in real‐clinical practice
por: Toublanc, Anne‐Claire, et al.
Publicado: (2022)

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
por: Hanvesakul, Raj, et al.
Publicado: (2023)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
por: Rittberg, Rebekah, et al.
Publicado: (2022)

PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
por: Knelson, Erik H., et al.
Publicado: (2021)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
por: Schultz, Christopher W, et al.
Publicado: (2023)

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2020)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin
por: Matsui, Shinji, et al.
Publicado: (2022)

Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer
por: Bhamidipati, Deepak, et al.
Publicado: (2023)

Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
por: Fernández-Teruel, Carlos, et al.
Publicado: (2021)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Lurbinectedin-induced thrombocytopenia: the role of body surface area
por: Papachristos, Apostolos, et al.
Publicado: (2022)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy
por: Schwander, Bjoern, et al.
Publicado: (2012)

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
por: Calvo, E., et al.
Publicado: (2017)

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
por: Olmedo, María Eugenia, et al.
Publicado: (2021)

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
por: Kundu, Kiran, et al.
Publicado: (2021)

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
por: Gros, Louis, et al.
Publicado: (2021)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights
por: Povo-Retana, Adrián, et al.
Publicado: (2020)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022)

Lurbinectedin improves macular edema in a case of central retinal vein occlusion()
por: Simona, Filippo, et al.
Publicado: (2022)

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity
por: Povo-Retana, Adrián, et al.
Publicado: (2023)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
por: Tummala, Tej, et al.
Publicado: (2023)

Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report
por: Wahab, Ahsan, et al.
Publicado: (2021)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
por: Rajappa, Senthil, et al.
Publicado: (2022)

Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction
por: Pathak, Surabhi, et al.
Publicado: (2021)

Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
por: Zheng, Li, et al.
Publicado: (2022)

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
por: Fudio, Salvador, et al.
Publicado: (2020)

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment
por: Nowaczyk, Alicja, et al.
Publicado: (2022)

An overview of treatment options for urinary stones
por: Shafi, Hamid, et al.
Publicado: (2016)

Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells
por: Costanzo, Federico, et al.
Publicado: (2022)

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
por: Fudio, Salvador, et al.
Publicado: (2023)

Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study
por: Wang, Xiangling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aabc3345iovekh06cuvolv7fl0